Sphera Funds Management’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.9M | Sell |
724,563
-38,000
| -5% | -$826K | 2.69% | 10 |
|
|
2025
Q4 | $16M | Buy |
762,563
+374,847
| +97% | +$6.54M | 3.1% | 4 |
|
|
2025
Q3 | $5.97M | Sell |
387,716
-1,183,848
| -75% | -$15.5M | 1.26% | 20 |
|
|
2025
Q2 | $14.7M | Sell |
1,571,564
-92,410
| -6% | -$1.02M | 3.45% | 4 |
|
|
2025
Q1 | $20.4M | Buy |
1,663,974
+282,733
| +20% | +$3.99M | 4.71% | 3 |
|
|
2024
Q4 | $18.3M | Buy |
1,381,241
+346,395
| +33% | +$5.93M | 3.3% | 4 |
|
|
2024
Q3 | $19.9M | Buy |
1,034,846
+212,799
| +26% | +$4.4M | 3.17% | 4 |
|
|
2024
Q2 | $16.9M | Buy |
822,047
+9,083
| +1% | +$190K | 2.3% | 7 |
|
|
2024
Q1 | $19.3M | Buy |
812,964
+40,000
| +5% | +$892K | 2.72% | 7 |
|
|
2023
Q4 | $16.7M | Sell |
772,964
-97
| -0% | -$1.49K | 2.69% | 6 |
|
|
2023
Q3 | $11.2M | Buy |
773,061
+50,000
| +7% | +$946K | 2.04% | 11 |
|
|
2023
Q2 | $15.1M | Buy |
723,061
+40,000
| +6% | +$833K | 2.36% | 8 |
|
|
2023
Q1 | $14.4M | Sell |
683,061
-27,500
| -4% | -$684K | 2.41% | 10 |
|
|
2022
Q4 | $18.1M | Sell |
710,561
-112,135
| -14% | -$2.62M | 3.88% | 7 |
|
|
2022
Q3 | $19.8M | Sell |
822,696
-316,633
| -28% | -$7.1M | 2.74% | 10 |
|
|
2022
Q2 | $21.9M | Sell |
1,139,329
-138,084
| -11% | -$2.3M | 2.34% | 12 |
|
|
2022
Q1 | $22.2M | Buy |
1,277,413
+100,828
| +9% | +$1.7M | 3.14% | 11 |
|
|
2021
Q4 | $25.8M | Buy |
1,176,585
+425,982
| +57% | +$7.87M | 2.83% | 7 |
|
|
2021
Q3 | $14.3M | Buy |
750,603
+203,416
| +37% | +$3.39M | 1.21% | 18 |
|
|
2021
Q2 | $9.39M | Sell |
547,187
-90,906
| -14% | -$1.67M | 0.64% | 44 |
|
|
2021
Q1 | $14.3M | Sell |
638,093
-107,807
| -14% | -$2.44M | 1.09% | 17 |
|
|
2020
Q4 | $16.6M | Buy |
745,900
+235,900
| +46% | +$4.89M | 1.47% | 15 |
|
|
2020
Q3 | $7.53M | Buy |
510,000
+290,000
| +132% | +$4.42M | 0.74% | 39 |
|
|
2020
Q2 | $3.26M | Buy |
220,000
+151,866
| +223% | +$2.31M | 0.31% | 63 |
|
|
2020
Q1 | $747K | Buy |
+68,134
| New | +$639K | 0.09% | 66 |
|
|
2018
Q2 | – | Sell |
-298,472
| Closed | -$4.25M | – | 124 |
|
|
2018
Q1 | $4.25M | Buy |
298,472
+50,000
| +20% | +$531K | 0.64% | 48 |
|
|
2017
Q4 | $2.18M | Hold |
248,472
| – | – | 0.26% | 92 |
|
|
2017
Q3 | $2.91M | Sell |
248,472
-47,838
| -16% | -$586K | 0.41% | 62 |
|
|
2017
Q2 | $4.14M | Buy |
296,310
+130,000
| +78% | +$1.49M | 0.7% | 40 |
|
|
2017
Q1 | $2.28M | Hold |
166,310
| – | – | 0.45% | 66 |
|
|
2016
Q4 | $1.19M | Hold |
166,310
| – | – | 0.3% | 79 |
|
|
2016
Q3 | $2.52M | Buy |
+166,310
| New | +$2.19M | 0.41% | 62 |
|
Other funds holding SNDX
KCM
VCM
DM
EP
KCM
HRCM
Sphera Funds Management's SNDX Position: Q1 2026 in Review
Sphera Funds Management reduced its Syndax Pharmaceuticals (SNDX) stake by 5% in Q1 2026, selling an estimated $826K and leaving 724,563 shares worth $16.9M. The position accounts for 2.69% of the portfolio, ranked #10.
Sphera Funds Management first reported a position in SNDX in Q3 2016 and has held it in 32 quarters since. The position peaked at $25.8M in Q4 2021. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.
- Sphera Funds Management held 724,563 shares of Syndax Pharmaceuticals worth $16.9M as of Q1 2026.
- Sphera Funds Management sold 38,000 Syndax Pharmaceuticals shares in Q1 2026, an estimated $826K.
- Syndax Pharmaceuticals made up 2.69% of Sphera Funds Management's portfolio in Q1 2026, its #10 holding.
- Sphera Funds Management first reported a position in Syndax Pharmaceuticals in Q3 2016 and has held it in 32 quarters since.
- Sphera Funds Management's Syndax Pharmaceuticals position peaked at $25.8M in Q4 2021.
- 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.
Based on Sphera Funds Management's 13F filing for Q1 2026, filed 15 May 2026.